- Home
- KPRX vs NVVE Comparison
KPRX vs NVVE Comparison
Compare KPRX & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KPRX | NVVE |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Oil Refining/Marketing |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 8.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KPRX | NVVE |
|---|---|---|
| Price | $2.20 | $3.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 6.0M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,630,156.00 |
| Revenue This Year | N/A | $892.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $1.98 |
| 52 Week High | $4.18 | $200.80 |
Technical Indicators
Market Signals| Indicator | KPRX | NVVE |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 54.37 |
| Support Level | $2.06 | $3.42 |
| Resistance Level | $2.30 | $4.18 |
| Average True Range (ATR) | 0.09 | 0.67 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 65.85 | 33.69 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.